Keyword Search
 
2018 | 2017 | 2016 | 2015
Motif Bio plc Announces Conversion of Convertible Promissory Notes, PDMR Dealing and Total Voting Rights
December 22, 2016
NEW YORK, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, announced that it has issued, in aggregate, 14,510,770 new ordinary shares in the Company ("Ordinary Shares") following the conversion by Amphion Innovations plc and Amphion Innovations US Inc., (the “Amphion Parties”) of the Convertible Promissory Notes (“CPNs”). The CPNs which totalled US$3,550,786 were conve... Read More
Motif Bio plc Announces Closing of its $25 Million U.S. Initial Public Offering and European Placement
November 23, 2016
NEW YORK, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, announced today the closing of its initial U.S. public offering of approximately 2.44 million American Depositary Shares (ADSs) with 50% warrant coverage. Each ADS, representing 20 ordinary shares of Motif, and warrant to purchase 0.5 ADSs were sold at a price to the public of $6.98 per ADS and warrant combinat... Read More
Motif Bio plc Announces Pricing Of $25 Million U.S. Initial Public Offering and European Placing
November 18, 2016
NEW YORK, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif)(NASDAQ:MTFB), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the pricing of its initial public offering in the United States of approximately 2.44 million American Depositary Shares (ADSs) with 50% warrant coverage. Each ADS, representing 20 ordinary shares of Motif, and warrant to purchase 0.5 ADSs are being offered at an offering price to the public of $6.98 per ADS and... Read More
Motif Bio Confirms Successful European Placing in Conjuction with U.S. Initial Public Offering and Nasdaq Capital Market Listing
November 18, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.  THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN MOTIF BIO PLC OR ANY OTHER ENT... Read More
Data Supporting Optimized Iclaprim Dosing in REVIVE Trial Presented at IDWEEK 2016
October 31, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONThis announcement contains inside informationMotif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that data were presented at IDWeek 2016 in New Orleans supporting the fixed dose of iclaprim designed to ... Read More
Update on Timing of Motif Bio Proposed U.S. Public Offering of American Depositary Shares, Ordinary Shares and Warrants and Application for NASDAQ Listing
October 31, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONThis announcement contains inside informationFurther to its announcement of 9 August 2016, Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it is continuing to work towards pricing of its propos... Read More
New Data on Iclaprim Released at IDWeek 2016; Iclaprim Shown to be Highly Potent Against SSSI and HABP Clinical Isolates
October 31, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONThis announcement contains inside informationMotif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that new data were presented on the antimicrobial activity of its lead antibiotic, iclaprim, against rece... Read More
Poster Presentation at ID Week
September 15, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONMotif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it will be presenting two poster studies at IDWeek, October 26 to 30 in New Orleans, USA.Motif Bio plc (AIM: MTFB), the clinical stage biopharmac... Read More
Issue of Equity
September 14, 2016
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces that it has issued, in aggregate, 409,000 new ordinary shares in the Company ("Ordinary Shares") as part of the terms of the renegotiated Convertible Promissory Notes with Amphion Innovations plc and Amphion Innovations US Inc., as previously announced on 8 September 2016.Application has been made for the 409,000 new Ordinary Shares to be admitted to trading on AIM ("Admi... Read More
Update on Revive-1 Phase 3 Clinical Trial
September 8, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONThis announcement contains inside informationMotif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces an update to REVIVE-1, one of Motif Bio's two Phase 3 clinical trials currently enrolling patients with A... Read More
Re-Negotiation of the Terms of the Convertible Promissory Notes
September 8, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONThis announcement contains inside informationMotif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it has re-negotiated the terms of the 1 April 2015 convertible promissory notes ("CPNs"), $1,471,700... Read More
Chief Medical Officer to Present at the World Anti-Microbial Resistance Congress
August 26, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that Dr. David Huang, Chief Medical Officer, will lead a panel discussion at the World Anti-Microbial Resistance Congress in Washington, USA on 9 September 2016.The discussion is titled: ‘In-licensing: Addressing the deficiencies in the original development program to develop a unique non-combination anti-infective'For further information on the conference please see:ht... Read More
Notification of Public Disclosure of Transactions by PDMR and Persons Closely Associated with them
August 22, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on 22 August 2016 it was notified that Amphion Innovations plc ("Amphion") had pledged an additional 11,655,480 ordinary shares of 1 penny each in the capital of Motif Bio as security to a draw-down of an additional tranche of Amphion's loan facility (the "Share Pledge").  In total, Amphion has pledged 27,961,625 ordinary shares in the Company in relation to t... Read More
Second Quarter and Half-Year 2016 Financial Results and Operational Progress
August 16, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONThis announcement contains inside informationMotif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces financial results for the second quarter and half-year ended June 30, 2016.Business UpdateOn March 2, 201... Read More
Update on Timing of Motif Bio Proposed U.S. Public Offering of American Depository Shares and Application for Nasdaq Listing
August 9, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONFurther to its announcement of 28 July 2016, Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that, as a result of market conditions, it has deferred pricing of its proposed public offering of Americ... Read More
Result of General Meeting
August 1, 2016
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the General Meeting held earlier today, all resolutions were duly passed.Notes to EditorsMotif Bio is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is be... Read More
Motif Bio Files Preliminary Prospectus for Proposed U.S. Public Offering of American Depository Shares and Applies for Nasdaq Listing
July 28, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONMotif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that, further to the notification on 13 July 2016 of the filing of a registration statement with the United States Securities and Exchange Commission ... Read More
Notification and public disclosure of transactions by PDMR and persons closely associated with them
July 18, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on 15 July 2016 it was notified that Amphion Innovations plc ("Amphion") had pledged an additional 1,400,000 ordinary shares of 1 penny each in the capital of Motif Bio as security to a draw-down of an additional tranche of Amphion's loan facility (the "Share Pledge").  In total, Amphion has pledged 16,306,145 ordinary shares in the Company in relation to the ... Read More
Motif Bio Files Registration Statement for Proposed U.S. Public Offering of American Depositary Shares and Applies for Nasdaq Listing
July 13, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed public offering of American Depositary Shares ("ADSs"). Motif Bio has also applied to have its ADSs listed on the NASDAQ Global Select Market under the ticker symbol "MTFB". Following completion of the offering of the ADSs, Motif Bio's o... Read More
Motif Bio Publishes Circular for Authority to Allot Up to 100 Million Ordinary Shares Pursuant to a Proposed U.S. Offering
July 13, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it is to publish today a Circular seeking authority to allot up to 100 million Ordinary Shares pursuant to a Proposed U.S. Offering. The Circular providing details of the Proposed US Offering will be posted to Shareholders, together with a Notice of General Meeting, today and will be available on the Company's website at www.motifbio.com. Download the Circular ... Read More
Directorate Change
July 1, 2016
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that Dr John Stakes III, Non-Executive Director, has resigned his position on the Board with immediate effect due to ill health.Richard Morgan, Chairman of Motif Bio, stated: "On behalf of the Board and shareholders I would like to thank John for his contribution to Motif Bio and his valuable support as we've made significant progress in the development of our lead compo... Read More
CEO Graham Lumsden presenting at BIO 2016
June 1, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that CEO Graham Lumsden has been invited to present at BIO 2016 which is being held at the Moscone Center, 747 Howard Street, San Francisco from June 6-9 2016.The presentation will provide information on the progress of its clinical lead antibiotic, iclaprim, into pivotal phase III trials and will be held in presentation room 1 on Monday June 6 commencing at 2.45pm.The ... Read More
Amphion Innovations plc
April 28, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, notes the announcement this morning by Amphion Innovations plc ("Amphion"), that Amphion has pledged 14,906,145 ordinary shares of 1 pence each in the capital of Motif Bio as security to a draw-down of an additional tranche of Amphion's loan facility.Graham Lumsden, CEO of Motif Bio, commented: "We welcome Amphion's continued commitment as a shareholder in Motif Bio."Motif Bio pl... Read More
Analyst & Investor conference call
April 25, 2016
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that following the conference call for analysts and investors that took place on Wednesday 20 April 2016 a playback facility is available until Wednesday 4 May 2016.Dial-in details for the replay are below:Dial-in0121 260 4861 (UK)1 866 268 1947 (US)+44 121 260 4861 (All other locations)Passcode3110627 (followed by #)In call instructionsPress 1 Play RecordingPress 2 Stop... Read More
Grant of share options to senior management
April 22, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has granted a total of 3,261,577 options to purchase ordinary shares of 1 pence each of Motif Bio ("Ordinary Shares").Pete A. Meyers, Chief Financial Officer, has been granted 2,961,577 options to purchase Ordinary Shares which vest over a four year period and are partially based on meeting certain performance targets. Rajesh B. Shukla Ph.D., Vice Presi... Read More
Annual Report and Accounts 2015 available on website
April 21, 2016
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that its Annual Report and Accounts 2015 is now available on its website in the investors section. Download the Annual Report and AccountsMotif Bio plcGraham Lumsden, Chief Executive Officer David Huang, Chief Medical Officer info@motifbio.comZeus Capital Limited (Nominated Advisor and Broker)Phil Walker / Dan Bate Dominic Wilson +44 (0) 20 3829 5000Nort... Read More
Final Results for the year ended 31 December 2015
April 20, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces its maiden full year audited financial results as an AIM-listed company.Corporate/operational highlights:AIM listing raising £2.8 million (before expenses) at 20 pence per share on 2 April 2015;The U.S. Food and Drug Administration (FDA) agreed to Phase III trials of iclaprim;QIDP designation granted by the FDA for iclaprim in ABSSSI and HABP in July 2015;Independent te... Read More
Notice of Results
April 18, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, will announce its financial results for the year ended 31 December 2015 on Wednesday 20 April 2016.The Company will hold an analyst and investor conference call at 12:00 BST (07.00 EST) on Wednesday 20 April 2016. The conference call will be hosted by Motif Bio's Chairman Richard Morgan and CEO Graham Lumsden and will cover the Company's full year results which will have been ann... Read More
Motif Bio makes new senior appointments
April 14, 2016
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces the appointment of Pete A. Meyers as Chief Financial Officer and Rajesh B. Shukla, Ph.D. as Vice President, Clinical Operations.Mr. Meyers joins the Company from TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG) where he was CFO and Treasurer. Prior to his role at TetraLogic, Mr. Meyers spent 18 years in health care investment banking, holding positions of incr... Read More
Motif Bio to present at BIO-Europe Spring
March 23, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has been selected to present at the 10th International Partnering Conference, BIO-Europe Spring® taking place at the Kistamässan Convention Center in Stockholm, Sweden over April 4-6.The presentation will be given by Dr. Graham Lumsden, CEO of Motif Bio and will take place in Room E6/7 (level 0) on Tuesday, April 5 2016 at 14:15 CET.BIO-Europe Spring® i... Read More
Appointment of strategic adviser
March 14, 2016
Fulford to seek commercialisation agreements for iclaprim outside the USAMotif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces the appointment of specialist adviser The Fulford Group Ltd ("The Fulford Group") to assist Motif in developing and implementing strategies to commercialise iclaprim, the Company's lead antibiotic currently in pivotal Phase 3 trials for the treatment of acute bacterial skin and skin structure infec... Read More
Motif’s Dr. David Huang on Nature’s “Combating Antibiotic Resistance” Webcast
March 9, 2016
... Read More
First patient dosed in iclaprim Phase 3 trials to treat skin infections
March 2, 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces the dosing of the first patient in two Phase 3 clinical trials of its lead antibiotic candidate iclaprim, for the treatment of acute bacterial skin and skin structure infections (ABSSSIs).The REVIVE (Randomized Evaluation IntraVenous Iclaprim Vancomycin TrEatment) clinical trials will assess the efficacy and safety of iclaprim compared to a standard of care antibiotic, ... Read More
Notification of Major Interest in Shares
February 23, 2016
... Read More
Motif Bio to participate in Webcast on Combating antibiotic resistance
February 22, 2016
Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that Dr. David Huang, Chief Medical Officer of Motif Bio, will participate in a BioPharma Dealmakers webcast, sponsored in part by Motif Bio, featuring five companies innovating antibiotic technologies. The webcast, part of the BioPharma Dealmakers series, is scheduled for 11:00 am ET on March 9.Webcast registration link >>The webcast will explore some of the ... Read More
Appointments of U.S. corporate finance adviser and auditor
January 25, 2016
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces today the appointment of U.S. healthcare investment bank MTS Health Partners (MTS) to advise on its future financing options within the U.S. market. A NASDAQ listing continues to be an option for Motif in order to be aligned with several peer companies.The Company has appointed as its auditor PricewaterhouseCoopers LLP (PwC), one of the top four multinational profession... Read More